Related Experiment Video

Updated: May 28, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge

Emmanuel Gachiniard1, Carla Berthault2, Marie Piroth2

  • 1Regional Pharmacovigilance Center, Nantes University Hospital, 44000 Nantes, France.

Therapie
|May 26, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Antiplatelet agentsDrug-induced lupus erythematosusPositive rechallengeTicagrelor

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Experiment Videos

Last Updated: May 28, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

Articles linked to this work by shared authors, journal, and citation graph.

PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.

Scientific reports·2026

French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Case Report: Pemetrexed-induced pseudocellulitis: a rare adverse effect to be recognized for better management.

Frontiers in oncology·2025

Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database.

Therapie·2025

Drug-induced fluorosis: A study based on the national and international pharmacovigilance databases.

Therapie·2025

Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.

The journal of allergy and clinical immunology. In practice·2024

[Five years of ISO 9001 certification in pharmacotoxicology: Experience feedback and implementation modalities in vigilance structures].

Therapie·2026

Epidemiology and risk factors of severe cutaneous drug reactions and evaluation through available databases.

Therapie·2026

Characteristics of patients with opioid/benzodiazepine use disorder in a specialized consultation unit for prescription drug addiction: A cross-sectional study.

Therapie·2026

Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.

Therapie·2026

[Biological pharmacology: A white paper].

Therapie·2026

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us